223 related articles for article (PubMed ID: 30903741)
1. Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy.
Bokhovchuk F; Mesrouze Y; Izaac A; Meyerhofer M; Zimmermann C; Fontana P; Schmelzle T; Erdmann D; Furet P; Kallen J; Chène P
FEBS J; 2019 Jun; 286(12):2381-2398. PubMed ID: 30903741
[TBL] [Abstract][Full Text] [Related]
2. A Sveinsson's chorioretinal atrophy-associated missense mutation in mouse Tead1 affects its interaction with the co-factors YAP and TAZ.
Kitagawa M
Biochem Biophys Res Commun; 2007 Oct; 361(4):1022-6. PubMed ID: 17689488
[TBL] [Abstract][Full Text] [Related]
3. Novel TEAD1 gene variant in a Serbian family with Sveinsson's chorioretinal atrophy.
Grubisa I; Jankovic M; Nikolic N; Jaksic V; Risimic D; Mavija M; Stamenkovic M; Zlatovic M; Milasin J
Exp Eye Res; 2021 Jun; 207():108575. PubMed ID: 33864784
[TBL] [Abstract][Full Text] [Related]
4. Yap and Taz regulate retinal pigment epithelial cell fate.
Miesfeld JB; Gestri G; Clark BS; Flinn MA; Poole RJ; Bader JR; Besharse JC; Wilson SW; Link BA
Development; 2015 Sep; 142(17):3021-32. PubMed ID: 26209646
[TBL] [Abstract][Full Text] [Related]
5. A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration).
Fossdal R; Jonasson F; Kristjansdottir GT; Kong A; Stefansson H; Gosh S; Gulcher JR; Stefansson K
Hum Mol Genet; 2004 May; 13(9):975-81. PubMed ID: 15016762
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics simulations study of influence of Tyr422Ala mutation on transcriptional enhancer activation domain 4 (TEAD4) and transcription co-activators complexes.
Niu RJ; Zheng QC; Zhang HX
J Theor Biol; 2019 Jul; 472():27-35. PubMed ID: 30978352
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes.
Pobbati AV; Chan SW; Lee I; Song H; Hong W
Structure; 2012 Jul; 20(7):1135-40. PubMed ID: 22632831
[TBL] [Abstract][Full Text] [Related]
8. The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences.
Hau JC; Erdmann D; Mesrouze Y; Furet P; Fontana P; Zimmermann C; Schmelzle T; Hofmann F; Chène P
Chembiochem; 2013 Jul; 14(10):1218-25. PubMed ID: 23780915
[TBL] [Abstract][Full Text] [Related]
9. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex.
Kaan HYK; Chan SW; Tan SKJ; Guo F; Lim CJ; Hong W; Song H
Sci Rep; 2017 May; 7(1):2035. PubMed ID: 28515457
[TBL] [Abstract][Full Text] [Related]
11. Alteration of TEAD1 expression levels confers apoptotic resistance through the transcriptional up-regulation of Livin.
Landin Malt A; Cagliero J; Legent K; Silber J; Zider A; Flagiello D
PLoS One; 2012; 7(9):e45498. PubMed ID: 23029054
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of YAP recognition by TEAD4 in the hippo pathway.
Chen L; Chan SW; Zhang X; Walsh M; Lim CJ; Hong W; Song H
Genes Dev; 2010 Feb; 24(3):290-300. PubMed ID: 20123908
[TBL] [Abstract][Full Text] [Related]
13. The surprising features of the TEAD4-Vgll1 protein-protein interaction.
Mesrouze Y; Hau JC; Erdmann D; Zimmermann C; Fontana P; Schmelzle T; Chène P
Chembiochem; 2014 Mar; 15(4):537-42. PubMed ID: 24504694
[TBL] [Abstract][Full Text] [Related]
14. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
[TBL] [Abstract][Full Text] [Related]
15. Structural insights into the YAP and TEAD complex.
Li Z; Zhao B; Wang P; Chen F; Dong Z; Yang H; Guan KL; Xu Y
Genes Dev; 2010 Feb; 24(3):235-40. PubMed ID: 20123905
[TBL] [Abstract][Full Text] [Related]
16. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD.
Mesrouze Y; Bokhovchuk F; Meyerhofer M; Fontana P; Zimmermann C; Martin T; Delaunay C; Erdmann D; Schmelzle T; Chène P
Elife; 2017 Apr; 6():. PubMed ID: 28430104
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
18. Retinal Degeneration Triggers the Activation of YAP/TEAD in Reactive Müller Cells.
Hamon A; Masson C; Bitard J; Gieser L; Roger JE; Perron M
Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):1941-1953. PubMed ID: 28384715
[TBL] [Abstract][Full Text] [Related]
19. Protein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex.
Pobbati AV; Rubin BP
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352993
[TBL] [Abstract][Full Text] [Related]
20. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
